logo-loader
Redx Pharma PLC

Redx Pharma plc - Director/PDMR Shareholding

RNS Number : 7371R
Redx Pharma plc
01 July 2020
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Share Purchases by Directors

 

Alderley Park, 1 July 2020 - Redx Pharma (AIM:REDX), the drug discovery and development Group focused on cancer and fibrosis, announces that it has been notified that Iain Ross, Non-executive Chairman, has on Tuesday 30 June acquired 215,870 Redx ordinary shares at the following prices: 

 

Number of Ordinary shares purchased

Price per share (pence)

86,881

17.25

53,989

18.50

35,000

19.75

40,000

22.50

 

Following this, Mr Ross will hold 215,870 ordinary shares in the Company, representing 0.11 per cent. of the issued share capital.

 

The Company also announces that Non-Executive Director Mr Peter Presland has on Tuesday 30 June acquired 118,849 Redx ordinary shares at a price of 25 pence per share. Mr Presland purchased the shares through his self-invested personal pension (SIPP).  Following this, Mr Presland will hold 118,849 ordinary shares in the Company, representing 0.06 per cent of the issued share capital.

 

-Ends-

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 918

Lisa Anson, Chief Executive Officer

James Mead, Chief Financial Officer

 

 

 

SPARK Advisory Partners (Nominated Advisor)

 T: +44 203 368 3550

Matt Davis/ Henry Todd

 

 

 

WG Partners LLP (Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin

 

 

About Redx Pharma Plc 

Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Iain Ross

2

Reason for notification

 

 

 

a.

Position/Status

Non -Executive Chairman

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Redx Pharma Plc

b.

LEI

213800HMS4EBXO589Y37

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary Shares of 1p each

 

ISIN: GB00BSNB6S51

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

86,881 at 17.25 pence per share

53,989 at 18.50 pence per share

35,000 at 19.75 pence per share

40,000 at 22.50 pence per share

d.

Aggregated information

- Aggregated Volume

- Price

215,870 at 18.94 pence per share

e.

Date of the transaction

30/06/20

f.

Place of the transaction

Outside of trading venue

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Peter Presland

2

Reason for notification

 

 

 

a.

Position/Status

Non-executive Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Redx Pharma Plc

b.

LEI

213800HMS4EBXO589Y37

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary Shares of 1p each

 

ISIN: GB00BSNB6S51

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

118,849

 

25 pence

d.

Aggregated information

- Aggregated Volume

- Price

N/A - Single Transaction

e.

Date of the transaction

30/06/20

f.

Place of the transaction

Outside of trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUAUARRNUBRAR
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma achieves milestone with dosing of first participant in Phase 1...

  Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion. RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's...

1 month ago

3 min read